RELATED PRODUCTS:

CGI-1746 (9647)

GDC-0853 (B2074) LFM-A13 (2414)

ONO-4059 (B1283) ONO-4059 analog (B1897)

RN-486 (9678) TP-0903 (9590)

Acalabrutinib (B1193-5,25) AVL-292 (Spebrutinib) (9413) BTK Inhibitor, CNX-774 (2600)

BTK Inhibitor, PCI-32765 (2298)

PRODUCT: GDC-0853

ALTERNATE NAMES:

(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2Hcyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one; Fenebrutinib

CATALOG NUMBER:

B2074-5,25

5 mg, 25 mg

AMOUNT:

STRUCTURE:



MOLECULAR FORMULA:	$C_{37}H_{44}N_8O_4$
MOLECULAR WEIGHT:	664.81
CAS NUMBER:	1434048-34-6
APPEARANCE:	White to off-white solid
SOLUBILITY:	DMSO
PURITY:	≥98% by HPLC
STORAGE:	Store at -20 °C. Protect from air and light
DESCRIPTION:	GDC-0853 is a potent and selective, Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. GDC- 0853 suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.
REFERENCES:	Crawford, J.J., et al. (2018). J. Med. Chem. 61, 227-2245.

HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure. USAGE:

FOR RESEARCH USE ONLY! Not to be used in humans